HomeANGLE plc


Lung Cancer Study Uses the ANGLE Parsortix System

ANGLE reports the study is being conducted by the Hellenic Oncology Research Group (“Hellenic”) lead by the Principal Investigators, Associate Professor Athanasios Kotsakis and Professor Vassilis Georgoulias of the IASO General Hospital in Athens, Greece and is investigating both ctDNA (circulating tumor DNA, fragments of dead cancer cells) and CTCs.

Enrolment Completed for Parsortix FDA Clinical Study for Metastatic Breast Cancer

3/7/19: Four leading US cancer centers, the University of Texas MD Anderson Cancer Center, the University of Southern California Norris Cancer Center, the University of Rochester Wilmot Cancer Center, and the Northwestern University Robert H Lurie Cancer Center completed enrolment of all of the required 400 evaluable subjects.